In 2024, the U.S. FDA granted HYRNUO Breakthrough Therapy designation for the treatment of adult patients with unresectable or metastatic NSCLC whose tumors have activating HER2 (ERBB2) mutations, and ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Kura Oncology for ...

Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises, ...

Unexplained weight loss can signal liver cancer, especially when accompanied by abdominal discomfort and persistent fullness. Changes in skin and eye ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did ...

Olutasidenib continued to demonstrate durable efficacy and a manageable safety profile in a broad range of patients with R/R mIDH1 AML, including those previously ...

"Komzifti provides a new treatment option for adults with relapsed or refractory AML who have limited treatment options," said Benito Fernandez, Chief Commercial Officer. "We are proud to partner with ...

Lung cancer stands as a formidable health challenge, claiming more lives globally than any other type of cancer. This ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company ...

While every soon-to-be parent hopes for a smooth, uneventful pregnancy, labor, and delivery, birth trauma and injury can be ...

A newly developed tool, called the DILI-Inpt prognostic score, can predict patients with drug-induced liver injury who are ...